Bevacizumab

Generic Name
Bevacizumab
Brand Names
Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
Drug Type
Biotech
Chemical Formula
-
CAS Number
216974-75-3
Unique Ingredient Identifier
2S9ZZM9Q9V
Background

There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...

Indication

As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...

Associated Conditions
Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Associated Therapies
First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment
Clinical Trials
Related News

A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

First Posted Date
2024-01-05
Last Posted Date
2024-08-01
Lead Sponsor
Outlook Therapeutics, Inc.
Target Recruit Count
400
Registration Number
NCT06190093
Locations
🇺🇸

Clinical Site, Silverdale, Washington, United States

Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer

First Posted Date
2023-12-28
Last Posted Date
2024-10-09
Lead Sponsor
Hebei Medical University Fourth Hospital
Target Recruit Count
173
Registration Number
NCT06184698
Locations
🇨🇳

The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

First Posted Date
2023-12-11
Last Posted Date
2023-12-27
Lead Sponsor
Melanoma and Skin Cancer Trials Limited
Target Recruit Count
46
Registration Number
NCT06163820

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

First Posted Date
2023-12-07
Last Posted Date
2024-11-19
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
134
Registration Number
NCT06160206
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

First Posted Date
2023-11-18
Last Posted Date
2024-12-20
Lead Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Target Recruit Count
186
Registration Number
NCT06139211
Locations
🇨🇳

Shanghai East Hospital, Shanghai, Shanghai, China

Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

First Posted Date
2023-11-15
Last Posted Date
2024-02-07
Lead Sponsor
Chang Gung Memorial Hospital
Target Recruit Count
45
Registration Number
NCT06133062
Locations
🇨🇳

Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study

First Posted Date
2023-11-09
Last Posted Date
2023-11-09
Lead Sponsor
Huihua Xiong
Target Recruit Count
78
Registration Number
NCT06125080
Locations
🇨🇳

Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

First Posted Date
2023-11-07
Last Posted Date
2024-11-21
Lead Sponsor
Bayer
Target Recruit Count
300
Registration Number
NCT06117891
Locations
🇺🇸

Mercy Medical Center - Medline Healthcare Services LLC, Baltimore, Maryland, United States

🇺🇸

University of Michigan Health System, Ann Arbor, Michigan, United States

🇺🇸

Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

and more 4 locations

First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients

Phase 4
Recruiting
Conditions
Carcinoma, Ovarian Epithelial
Interventions
Drug: Olaparib
Drug: Bevacizumab
First Posted Date
2023-11-07
Last Posted Date
2023-11-07
Lead Sponsor
Mario Negri Institute for Pharmacological Research
Target Recruit Count
190
Registration Number
NCT06121401
Locations
🇮🇹

Azienda Socio Sanitaria Territoriale (ASST) Lariana, San Fermo Della Battaglia, Como, Italy

🇮🇹

Istituto Oncologico Veneto IRCCS, Padova, Italy

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

First Posted Date
2023-10-31
Last Posted Date
2024-12-12
Lead Sponsor
AbbVie
Target Recruit Count
660
Registration Number
NCT06109272
Locations
🇮🇹

Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 265506, Rome, Roma, Italy

🇺🇸

City of Hope /ID# 261468, Duarte, California, United States

🇺🇸

City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669, Irvine, California, United States

and more 34 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy